Theravance and Mylan Sue Chinese Firm Over Alleged COPD Drug Patent Infringement

Theravance Biopharma and Mylan Specialty have initiated legal action against a Chinese pharmaceutical company, alleging that the firm has replicated their chronic obstructive pulmonary disease (COPD) medication, Yupelri. The companies claim this action has led to patent infringements concerning multiple aspects of the drug. The lawsuit underscores ongoing challenges within the pharmaceutical industry, particularly regarding intellectual property and international competition. For additional details, refer to the original article on Law360.